Wednesday, July 8, 2026

Patent intelligence · US

US 11352316

Opioid receptor modulators and products and methods related thereto

granted A61PA61P23/00A61P25/00
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 16
Applicant portfolio 82
Patent details — US 11352316
Jurisdiction
US
Status
granted
Grant date
Jun 7, 2022
Expiration
Jun 2, 2042
Applicant
EPIODYNE, INC.
Claims
20
CPC classes
A61P, A61P23/00, A61P25/00
View on Google Patents ↗

Quick answer

US 11352316 (Opioid receptor modulators and products and methods related thereto) is held by EPIODYNE, INC.. Status: granted. Granted Jun 7, 2022. Expires Jun 2, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
EPIODYNE, INC.
Grant date
Expiration
Claims
20
CPC classes
A61P, A61P23/00, A61P25/00

More from EPIODYNE, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12428487

    Complexes comprising an anti-transferrin receptor antibody linked to an oligonicleotide and method of delivering oligonucleotide to a subject

    Dyne Therapeutics, Inc. · Expires Sep 25, 2045

    granted
  2. US 12403203

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Expires Aug 28, 2045

    granted
  3. US 12397062

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Expires Aug 21, 2045

    granted
  4. US 12370264

    Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject

    Dyne Therapeutics, Inc. · Expires Jul 24, 2045

    granted
  5. US 12357703

    Muscle-targeting complexes comprising an anti-transferin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping

    Dyne Therapeutics, Inc. · Expires Jul 10, 2045

    granted
  6. US 12329824

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Dyne Therapeutics, Inc. · Expires Jun 12, 2045

    granted
  7. US 12329825

    Muscle targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping of exon 44 of dystrophin in a subject

    Dyne Therapeutics, Inc. · Expires Jun 12, 2045

    granted
  8. US 12325753

    Method of using an anti-transferrin receptor antibody to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy

    Dyne Therapeutics, Inc. · Expires Jun 5, 2045

    granted

Frequently asked questions

What is US patent 11352316?

US 11352316 (Opioid receptor modulators and products and methods related thereto) is held by EPIODYNE, INC.. Status: granted. Granted Jun 7, 2022. Expires Jun 2, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11352316?

EPIODYNE, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 82 pharmaceutical patents for this assignee.

When does US 11352316 expire?

Our index shows an expiration date of Jun 2, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.